Firmagon
(degarelix)ApprovedSmall molecule
FerringDegarelix is used to treat advanced prostate cancer by lowering testosterone levels in the body, which helps slow or stop cancer growth.[2] Firmagon is currently approved and in use across 16 indications[4].[1]
Firmagon is one of 319 small molecule programs targeting Prostatectomy. It is currently in Approved.
16
Indications
110
Total Trials
26
Active Trials
318
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Firmagon
FerringApproved
Cabometyx
Bristol-Myers SquibbPhase 3
Verzenio
Eli LillyPhase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
Antibiotic
PfizerPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
INR101
YYunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
HC-1119
HHinova Pharmaceuticals Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer69 trials
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
Completed·—·Phase 1·NCT02324998·20 enrolled
Show 66 more trials
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Completed·—·Phase 1·NCT04301414·26 enrolled
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT02799706·885 enrolled
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Recruiting·—·Phase 2·NCT04734730·70 enrolled
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
Completed·—··NCT04897958·14,417 enrolled
Metastatic Prostate Cancer6 trials
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 4·NCT03202381·35 enrolled
Show 3 more trials
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled
Prostate Adenocarcinoma5 trials
Show 2 more trials
Prostatectomy3 trials
24 more indications
Breast Cancer1 trial
Toxicity1 trial
Ovarian Hyperstimulation1 trial
Bladder Cancer1 trial
Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer
Unknown status·—··NCT04282876·60 enrolled
COVID-191 trial
Cardiovascular Disease1 trial
Endometriosis1 trial
Degarelix in the Treatment of Endometriosis Recurrence
Completed·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 3·NCT01712763·360 enrolled
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Neoadjuvant1 trial
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Recruiting·—·Phase 1·NCT05839119·32 enrolled
Breast Cancer Invasive1 trial
Male Breast Cancer1 trial
Recurrent Castration-Sensitive Prostate Carcinoma1 trial
Castration Sensitive Prostate Cancer1 trial
Regulatory
FDA Approval Timeline[5]
Dec 24, 2008
FIRMAGON
NDA NDA022201
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Firmagon drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for degarelix. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]